MBZIRC
28.9.2021 13:46:05 CEST | Business Wire | Press release
The Mohamed Bin Zayed International Robotics Challenge (MBZIRC) will be held in the UAE capital, Abu Dhabi, in June 2023, where tech innovators will participate to seek marine safety and security solutions to take home more than US$3 million in prize money.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005641/en/
Organised by ASPIRE, the dedicated technology programme management pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology research body in Abu Dhabi, UAE, the MBZIRC is held every two years. The upcoming edition, called MBZIRC Maritime Grand Challenge, focuses on real-time solutions to maritime safety and security challenges and seeks to claim its place among the largest and most prestigious AI and robotics competitions in the world.
The Challenge is open to international universities, research institutions, companies and individual innovators from all over the world. It will involve a heterogeneous collaboration among unmanned aerial vehicles and unmanned surface vehicles, to perform complex navigation and manipulation tasks in a GNSS-denied environment. Call for registrations is now open.
Commenting on the announcement, H.E. Faisal Al Bannai , Secretary General of ATRC, said: “We are proud that MBZIRC is going global by inviting the best talent from all over the world to participate. We have set a tough real-world challenge that will push the participants to the limits of their capabilities. The event is a great opportunity to demonstrate the pioneering scientific research work that is taking place in Abu Dhabi and the UAE.”
The challenge will show how both entities focus on niche areas of technology, while attracting global innovators to stimulate ideas, encourage collaboration, and push boundaries in advanced technologies to find systems solutions to global challenges.
“For countries with long coastlines, ensuring maritime safety requires significant investment in sophisticated equipment and highly trained personnel. Using advanced robotic systems can not only help reduce costs, but also handle some of the often- dangerous tasks performed by humans. The motivation for holding the MBZIRC Maritime Grand Challenge is to take the technology out of the laboratory and test it in a real-world environment to see what is possible,” said Dr Arthur Morrish, Chief Executive of ASPIRE.
Dr Morrish underscored the two-fold purpose behind the competition: one is to focus on the important problems in autonomy of robotics while engaging the world community in a hard robotics challenge. The other is to find a solution to a real-world challenge facing the world.
The challenge is for a swarm of UAVs to identify a target vessel from several similar vessels in open waters in a GNSS-denied environment, and to offload specific items from the target onto an USV in the shortest possible time using autonomous technologies. This is a new kind of kind of exercise in autonomous robotics. “A nice thing about this challenge is that you tell people what you want, but you don’t specify an approach to do it,” Dr Morrish added.
He said that this kind of a smart system will have practical application in other areas as well, especially as it can perform complex tasks of autonomous intervention in a GNSS-denied environment.
For more information, visit www.mbzirc.com
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005641/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
